Aripiprazole Prolonged-Release-Suspension-Injection
Indication
Maintenance treatment of schizophrenia in adult patients
Red
Brand:
Abilify Maintena®
Nice TA:
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Central nervous system
Background
Aripiprazole prolonged-release (PR) suspension for injection is recommended as a treatment option in the maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole where both of the following criteria are met;
- where treatment is in line with the recommendations within NICE CG178 for the use of depot or long-acting injectable antipsychotic medication and
- where treatment is in line with the Lancashire Care Guidance for Prescribing Second Generation Long Acting Antipsychotic Injections
Recommendation
LSCMMG Recommendation:
Red
Reason for decision:
Specialist medicine
Supporting documents: